Publications by authors named "A M Dyrhol-Riise"
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFBackground: There is an unmet need for treatment of long-term symptoms following COVID-19. Remdesivir is currently the only antiviral approved by the European Medicines Agency for hospitalised patients. Here, we report on the effect of remdesivir in addition to standard of care on long-term symptoms and quality of life in hospitalised patients with COVID-19 as part of the open-label randomised NOR-Solidarity trial (NCT04321616).
View Article and Find Full Text PDFThe COVID-19 pandemic posed a challenge for people living with HIV (PLWH), particularly immune non-responders (INR) with compromised CD4 T-cell reconstitution following antiretroviral therapy (CD4 count <350 cells per mm). Their diminished vaccine responses raised concerns about their vulnerability to SARS-CoV-2 breakthrough infections (BTI). Our in-depth study here revealed chronic inflammation in PLWH and a limited anti-Spike IgG response after vaccination in INR.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore how the relationship between SARS-CoV2 viral load (VL) and inflammation markers changes over time in hospitalized COVID-19 patients and if these markers can predict severe health outcomes.
- Researchers collected samples from 160 patients and found that higher levels of specific inflammatory markers at admission were linked to severe outcomes, while the association between VL and inflammation markers strengthened in the days following hospitalization.
- The findings suggest that certain inflammatory markers, particularly when combined with high VL, could help identify severe cases, leading to potential changes in treatment approaches that use both antiviral and anti-inflammatory strategies.
Antiretroviral treatment (ART) has converted HIV from a lethal disease to a chronic condition, yet co-morbidities persist. Incomplete immune recovery and chronic immune activation, especially in the gut mucosa, contribute to these complications. Inflammasomes, multi-protein complexes activated by innate immune receptors, appear to play a role in these inflammatory responses.
View Article and Find Full Text PDF